View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
April 23, 2020

Treatment of cardiovascular disease during the Covid-19 pandemic

By Magdalena Dugdale

As Covid-19 moves through the global population at an alarming rate, with over two million confirmed global cases since December, data-based research and further understanding of the virus is paramount to improving the preparation and management of patients and the general population.

Moreover, it is vital to understand the at-risk population to minimise the burden on global healthcare structures and maintain high-quality patient care. Cardiovascular disease (CVD) has been found to be a risk factor for patients and those with CVD are therefore categorised as a vulnerable patient group. However, new research has shown that although those with CVD are at risk, cardiac injury can occur in those with confirmed Covid-19 and no previous cardiovascular (CV) risk. This will increase the use of and the demand for various CV treatments as patients are treated symptomatically and potentially longer-term if the myocardium effects are long-lasting.

Click here to read more from the full article.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU